Regulatory approval gives green light for trial to proceed 20 July 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company
OneThree Biotech completes build and optimisation of AI model for RSV data – results to come in H2
Further expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Update on POLB 001 Clinical Development
Poolbeg to engage with key international stakeholders at congress as it develops an intramuscular Melioidosis vaccine candidate
Results of the proposal to purchase shares from Distribution in Specie shareholders
Continued expansion of the POLB 002 patent family following European Patent Office approval
Proposal to Purchase Shares from Distribution in Specie Shareholders
On track to commence LPS human challenge clinical trial in June 2022
Poolbeg makes excellent progress post IPO and momentum building
New treatments for infectious disease to be identified through analysis of human challenge trial data
